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Abstract
Rett syndrome is caused by mutations in the X-linked MECP2 gene, which encodes a chromosomal protein that binds to
methylated DNA. Mouse models mirror the human disorder and therefore allow investigation of phenotypes at a molecular
level. We describe an Mecp2 allelic series representing the three most common missense Rett syndrome (RTT) mutations,
including ﬁrst reports of Mecp2[R133C] andMecp2[T158M] knock-in mice, in addition to Mecp2[R306C] mutant mice. Together
these three alleles comprise∼25%of all RTTmutations in humans, but they vary signiﬁcantly in average severity. This spectrum
ismimicked in themousemodels; R133C being least severe, T158Mmost severe and R306C of intermediate severity. Both R133C
andT158Mmutations cause compound phenotypes at themolecular level, combining compromisedDNAbindingwith reduced
stability, the destabilizing effect of T158M being more severe. Our ﬁndings contradict the hypothesis that the R133C mutation
exclusively abolishes binding to hydroxymethylated DNA, as interactions with DNA containing methyl-CG, methyl-CA and
hydroxymethyl-CA are all reduced in vivo.We ﬁnd thatMeCP2[T158M] is signiﬁcantly less stable thanMeCP2[R133C], whichmay
account for the divergent clinical impact of the mutations. Overall, this allelic series recapitulates human RTT severity, reveals
compound molecular aetiologies and provides a valuable resource in the search for personalized therapeutic interventions.
Introduction
Mutations in the X-linked MECP2 gene are implicated in several
human disorders characterized by developmental delay and
intellectual disability, including Rett syndrome (RTT) (1) and
MECP2 duplication syndrome (2). RTT is a conditionwith postnatal
onset that predominantly affects girls, as males fail to survive be-
yond infancy. Animalmodels haveproveduseful for improving our
understanding of MeCP2 function and for explaining in molecular
terms the origin of the RTT phenotype. The ﬁrst mouse models
were simple loss-of-function alleles caused by gross deletion
of most of the coding sequence (3,4), but knock-in mutations cor-
responding to speciﬁc RTT-causing mutations (5,6) offer the op-
portunity for deeper understanding. Of particular interest are
missense RTT mutations leading to the substitution of a single
amino acid, as these pinpoint critical regions of the protein that
cannot be deduced from frameshift and nonsense mutations, or
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mutations that affect splicing (7). Importantly, human and mouse
MeCP2 arehighlyhomologous proteins, being∼95% identical at the
aminoacid level across∼500 amino acids. This stringent functional
conservation over evolutionary timemakes it likely thatmutations
in themouse geneprovide appropriatemodels for determining the
molecular aetiology of the human disorders.
In this study, we generated knock-in mice for the three most
common RTT missense mutations: T158M, R306C and R133C,
which together account for ∼25% of all RTT cases. The most fre-
quent of all RTT mutations is T158M (∼12% of cases), followed by
R306C (∼9%) and R133C (∼5%) (8). Two of the three mutations
(T158M and R133C) localize to the methyl-CpG binding domain
(9), and previous in vitro studies suggest that both can adversely
affect DNA binding (10–12). The R306Cmutation is locatedwithin
the recently deﬁned NCoR/SMRT Interaction Domain (NID) (13).
This mutation, like others close by, prevents MeCP2 from in-
teracting with the NCoR/SMRT corepressor complex and inhi-
bits transcriptional repression in cell-based assays. Although all
three mutations result in ‘classical’ RTT symptoms, there is a
clear difference between them when clinical severity rating
scales frommany patients are analysed (8,14). T158M is more se-
vere than R306C on average. Least severe of the most frequent
RTT mutations is R133C, which is more often associated with
preservation of walking and/or speech (8). We sought to explain
this clinical spectrum in molecular terms.
The R133Cmutationhas not previously beenmodelled inmice,
but it has been proposed that its milder phenotype is due to reten-
tion of binding to 5-methylcytosine accompanied by loss of bind-
ing to hydroxymethylcytosine (hmC) (15). Mice with the T158A
RTTmutation were characterized (6), but themuchmore common
T158M RTT allele has not yet been reported. The R306C mutation
has been shown to cause Rett-like phenotypes in knock-in mice
(13), and mice bearing an integrated mutant transgene have been
comprehensively phenotyped (16). Here, we focus on the compara-
tive phenotypes caused by these threemutants atmolecular, cyto-
genetic and behavioural levels. This was achieved by comparing
lines of male mice expressing MeCP2 variants from the endogen-
ous Mecp2 locus as fusions with the reporter protein enhanced
green ﬂuorescent protein (EGFP), including wild type (WT). We
ﬁnd that these RTT mutations recapitulate the severity spectrum
of human RTT, and they offer a molecular explanation for this
phenotypic range. In particular, the R133Cmutant proteinhas a re-
duced afﬁnity for all known MeCP2 target sequences, including
methyl-CG (mCG) and is signiﬁcantly reduced in abundance. We
conclude that the RTT-like phenotype cannot be exclusively attrib-
utable to loss of hmC binding by this mutant protein as previously
proposed (15). The greater severity of the T158M mutation is ex-
plained by more extreme destabilization of the protein, coupled
with reduced afﬁnity for modiﬁed DNA. This ﬁnding mirrors that
reported previously for a less frequent allele, T158A, affecting the
same amino acid (6). R306C, which has lost the ability to interact
with the NCoR/SMRT co-repressor, persists atWT levels and large-
ly retainsWT chromatin binding characteristics. ThisMecp2 allelic
series allows resolution of the compound phenotypes underlying
these causes of RTT. In addition, the studysupports available prog-
nostic information regarding Rett syndrome and provides a re-
source in the search for individualized therapeutic approaches.
Results
WT MeCP2-GFP mice are essentially phenotypically WT
We generated an allelic series in which endogenous Mecp2 or
mutant Mecp2 genes were fused in frame with EGFP at their
C-termini (Fig. 1A; Supplementary Material, Fig. S1). Mice expres-
sing knock-in WT MeCP2-EGFP fusion genes have been reported
(13,17), but without extensive characterization. We initially
looked for phenotypic defects due to the fusion of WT MeCP2
with EGFP by monitoring male mice at the molecular and
whole organism levels. Analysis of hemizygous males has the
advantage that phenotypic severity is not inﬂuenced by the pat-
tern of X chromosome inactivation, and so severity of individual
mutations can be assessed in an unbiased fashion. Quantitative
polymerase chain reaction (PCR) andwestern blots indicated that
bothmRNA and protein products of theMecp2-GFP gene (WT-GFP)
were expressed in brain, though at somewhat higher levels than
the endogenous Mecp2 gene (WT) (Fig. 1B and C). Quantitative
western blots suggested that the level of WT-GFP is ∼1.6-fold
higher than in untagged WT littermates. At the whole organism
level, we analysed cohorts ofWT-GFPmice back-crossed for four
generations to give a genetic background that is ∼94% C57BL/6J.
WT-GFP knock-in mice were fertile and showed normal survival
but tended to be smaller than WT littermates (Fig. 1D and E). Co-
horts were monitored using a phenotypic scoring methodology
that records breathing, tremor, gait, hindlimb clasping, mobility
and general condition (18). This series of observational tests
has the advantage that it is not affected by learning and can
therefore be performedweekly over long periods, giving reprodu-
cible results. Using this method,WT-GFPmice showed no signiﬁ-
cant phenotypic deterioration compared with WT littermates
(Fig. 1F), reinforcing the view that, despite the presence of the
EGFP tag, they are essentially WT.
To search for neurological phenotypes inmore detail, we sub-
jectedWT-GFPmice to a series of motor coordination and behav-
ioural tests (Fig. 1G–I). Performance on the elevated plus maze
was indistinguishable from WT and on the accelerating rotarod
was also not signiﬁcantly different from WT littermates. The
hanging-wire test showed a weak but reproducible reduction in
the ability to engage hindlimbs with the wire. We noted in add-
ition that there was a trend towards a mild reduction in weight
and a trend towards defective rotarod performance, but neither
achieved signiﬁcance. These very weak phenotypic effects may
be attributable to the over-expression of MeCP2-GFP relative to
untagged protein. Taking the ﬁndings together, however, we con-
clude that the addition of the C-terminal EGFP epitope and the
moderate over-expression of the protein have minimal pheno-
typic consequences by these assays.
Allelic series of RTT missense mutations recapitulates
severity in humans
Using the same knock-in technology, we generated the following
mouse lines: Mecp2[T158M]EGFP, Mecp2[R306C]EGFP and Mecp2
[R133C]EGFP, referred to as T158M-GFP, R306C-GFP and R133C-
GFP, respectively. Both MeCP2 isoforms, which differ only at
their extreme N-termini, are affected by the knock-in. Each line
was back-crossed to obtain a predominantly C57BL/6J genetic
background equivalent to that of the WT-GFP mice (94%). Each
of themutants gave rise tomales that exhibited overt phenotypic
defects from ∼6 weeks of age (see below), but their survival pro-
ﬁles were very different (Fig. 2A). T158M-GFP male survival was
slightly prolonged comparedwithMecp2-nullmice fromprevious
analyses (18) (median survival 13weeks comparedwith 9weeks),
whereas R306C-GFPmales survived signiﬁcantly longer (median
= 30 weeks). R133C-GFP males were most mildly affected, with a
median survival of 42 weeks.
Phenotypic scoring of T158M-GFP, R306C-GFP and R133C-GFP
mice matched survival curves and provided detail regarding
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progression (Fig. 2B). T158M-GFP male mice acquired a range of
phenotypic traits rapidly over a few weeks, whereas R306C-GFP
mice, after an initially rapid onset, remained phenotypically rela-
tively stable until 33weeks, at which timephenotypes of survivors
became more severe. Interestingly, this late inﬂection point coin-
cides with an age identiﬁed previously as being particularly sensi-
tive to MeCP2 deﬁciency (19). R133C-GFP males showed a more
gradual build-up of phenotypic defects compared with either
R306C-GFP or T158M-GFP. Weight proﬁles revealed that all themu-
tantswere lighter thanWT-GFPanimals of equivalent age (Fig. 2C).
Cohorts of the allelic series underwentmotorcoordinationandbe-
havioural testing at 8–10 weeks of age at which time T158M-GFP,
R306C-GFPandR133C-GFPmice scored5.4, 2.8 and1.4, respectively,
using the observational scoring method (see Fig. 2B). None of the
mutants performed as well as their correspondingWT littermates
on the hanging wire and elevated plus maze (Fig. 3A and C).
T158M-GFP and R306C-GFP were also signiﬁcantly compromised
as assayed by the 3-day accelerating rotarod-learning paradigm
(Fig. 3E), but R133C-GFP mice showed no detectable defects
compared with WT in this test.
Figure 1.WT-GFPmice showminimal overt phenotype. (A) Schematic representation ofMeCP2with an EGFP tag.Missensemutations analysed in this study (T158M, R133C
and R306C) are shown in relation to the MBD and NID. (B) Levels (mean ± SD) of Mecp2 transcripts in WT-GFP mouse brain (n = 9) compared with WT littermates (n = 9),
expressed relative to Cyclophilin A transcript (CycA). (C) Representative western blot and quantiﬁcation comparing MeCP2 protein abundance in WT-GFP mouse brain
(double arrow-head, n = 6) versus WT littermates (single arrow-head, n = 6). Gamma tubulin (GT) served as an internal control. Mean ± SEM plotted. (D) The Kaplan–
Meyer plots showing survival of WT-GFP mice (n = 8) compared with their WT littermates (n = 8) and Mecp2-null mice [Ref. (18)] (n = 24). (E) Growth curve showing
average weight of WT-GFP mice (n = 8) compared with their WT littermates (n = 8). Using repeated measures ANOVA, the difference was consistent and signiﬁcant
(P < 0.001) over time, but at any single time point, the difference was not signiﬁcant. (F) Phenotypic scoring (see the text) of WT-GFP or WT mice. For comparison,
Mecp2-null scoring is shown. (G–I) WT-GFP mice (n = 9) and their WT littermates (n = 10) were compared using three behavioural tests: (G) the hanging-wire test, (H) the
elevated plus maze, and (I) the accelerating rotarod showing individual mean latencies (dots) and cohort mean latency (line) for each of three days of trials. Statistical
analysis took all trials into account. Statistical tests were unpaired two-tailed t-test (B, C and E) and the Kolmogorov–Smirnov test (G–I). All behavioural paradigms
were conducted on animals aged 8–10 weeks, and biochemical analyses were conducted using tissues from adults aged 6–12 weeks. Asterisks denote the following P
values: *P < 0.05, **P < 0.01 and ***P < 0.001.
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In these analyses, WT littermates lacked the GFP tag on en-
dogenous MeCP2, but as shown in Figure 1, the presence of this
tag has minimal phenotypic consequences. We conﬁrmed that
the presence of C-terminal GFP was not contributing to pheno-
type by comparing the performance of mutant-GFP mice with
age-matched WT-GFP mice in the same tests (Fig. 3B, D and F).
Comparison between litters of different lines in this way is less
well controlled, as illustrated by the variability of WT test scores
in Figure 3A and C. Nevertheless, we observed that both R133C
and R306C mice performed signiﬁcantly less well than WT-GFP
in the hanging-wire and rotarod tests, while performance of
T158M mice in both elevated plus maze and rotarod was signiﬁ-
cantly inferior. In cases where differences between mutant and
WT-GFP mice did not reach statistical signiﬁcance (R133C and
R306C in the elevated plus maze, and T158M on the hanging-
wire test), the data showed trends towards defective performance
that matched those detected in the comparison with littermates.
The behavioural analyses therefore conﬁrm phenotypic scoring
and survival data in showing that the Rett missense mutations
are responsible for the observed phenotypes.
Heterozygous females show RTT-like phenotypes
Rett syndrome affects females who are heterozygous for these
MECP2 mutations and consequently mosaic for expression of WT
ormutant alleles, due to X-chromosome inactivation. Inmice, het-
erozygotes for the null allele showa delayed-onset phenotype that
is usually detectable between 4 and 12 months of age. We com-
pared phenotypic scores of heterozygotes for each mutation over
∼12 months. WT-GFP female heterozygotes were not scored in
this fashion as they invariably displayed no signs of disease up to
at least 1 year. All had RTT-like symptoms, with R133C-GFP and
R306C-GFP being less severe than T158M-GFP (Supplementary Ma-
terial, Fig. S2). In this respect, also thephenotypes of these frequent
RTT mutations in mice reﬂect the spectrum of human severity.
MeCP2 R133C-GFP and T158M-GFP show reductions in
both abundance and chromatin binding in neurons
The matching spectrum of severity between humans and mice
with respect to T158M-GFP, R306C-GFP and R133C-GFP mutations
provides validation that the mouse models are an appropriate
system to investigate the mechanism by which these mutations
cause RTT in humans. We used cell biological and biochemical
techniques to understand the reasons for compromised MeCP2
function. At the level of mRNA, expression of the Mecp2-GFP
knock-in alleles in brain was somewhat elevated compared
with the native Mecp2 gene, except in the case of R133C-GFP
(Fig. 4A). In agreement with the mRNA analysis, WT-GFP and
R306C-GFP proteins were 1.5-fold more abundant than native
MeCP2 in the brain, with the expression of R306C-GFP modestly
reduced relative to WT-GFP (Fig. 4B). In contrast, R133C-GFP pro-
tein was reduced to ∼55%, and T158M-GFP was present at only
∼30% of WT-GFP by western blotting (Fig. 4B and Supplementary
Material, Fig. S3A) and ﬂuorescence-activated cell sorting
(Supplementary Material, Fig. S3B). Abundance was therefore
equivalent to approximately 95 and 50% of untagged MeCP2 for
R133C-GFP and T158M-GFP, respectively. Reduced stability of
T158A, a distinct allele of T158, was reported previously (6), mak-
ing it likely that this is an intrinsic property of MeCP2 lacking the
hydrogen-bonding capability of threonine at this position (20). To
determinewhether themore subtle reduction in R133C-GFP seen
in the brains is speciﬁc to this particular mouse line or is a repro-
ducible property of the mutant protein, we analysed embryonic
stem cell-derived neurons in culture using an independent
knock-in clone. Again R133C-GFP was present at approximately
half the level ofWT-GFP, suggesting that themutation itself is re-
sponsible for the deﬁciency, probably due to compromised RNA
or protein stability (Supplementary Material, Fig. S3C). This rela-
tionship was also seen with an alternative WT-GFP clone (data
not shown).
Figure 2. The Mecp2-GFP allelic series mimics the clinical severity of equivalent human mutations. (A) The Kaplan–Meyer plots showing reduced survival of T158M-GFP
(red), R306C-GFP (blue) and R133C-GFP (green) mutants in comparison withWT-GFP (dark grey) andMecp2-null (light grey) mice (18). Statistical signiﬁcance is denoted as
follows: *P < 0.05, **P < 0.01 and ***P < 0.001 (Mantel-Cox test) and calculated in comparison with the WT-GFP mice. (B) Graph showing average phenotypic score for each
cohort over time. (C) Graph showing averageweight over time. Cohorts comprisedWT-GFP (n = 8), R133C-GFP (n = 10), R306C-GFP (n = 11), T158M-GFP (n = 11) andMecp2-null
mice (n = 12–24). A cross indicates that all mice in the cohort had been culled by this time point due to severity of the RTT-like phenotype.
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Taking advantage of GFP immunoﬂuorescence, we examined
localization of the different MeCP2 variants in hippocampal sec-
tions of hemizygous male mouse brains (Fig. 4C). The intensities
of nuclear EGFP immunoﬂuorescence in brain sections con-
ﬁrmed qualitatively that in comparison with WT-GFP protein,
R306C-GFP expression was similar, R133C-GFP expression was
moderately reduced and T158M-GFP was severely reduced
in the brain. We focussed on sub-nuclear localization of the
MeCP2 variants, as about half of all 5-methylcytosine in the
mouse genome is concentrated in pericentromeric foci due to
the abundance and CG richness of mouse satellite DNA se-
quences. Native MeCP2 localized to pericentromeric foci in a
DNA methylation-dependent manner (21) as did WT-GFP and
R306C-GFP fusion proteins. R133C-GFP and T158M-GFP, however,
Figure 3. Behavioural analysis of theMecp2-GFP allelic series indicates that R133C-GFPmice are less severely affected than R306C-GFP and T158M-GFP. Mutant males and
WTmale littermates underwent behavioural analysis as in Figure 1. (A) Hanging-wire test, (C) elevated plus maze and (E) accelerating rotarod. R133C-GFP (n = 10, green)
plus WT littermates (n = 13, grey); R306C-GFP (n = 10–11, blue) plus WT littermates (n = 9, grey); T158M-GFP (n = 7, red) plus WT littermates (n = 6, grey). B, D and F show
comparisons between mutant males and WT-GFP males in the same series of tests. (E and F) Graphs showing mean time to descent for individuals (dots) and cohorts
(lines) for each trial day. Statistical analysis took all trials into account, and signiﬁcance is denoted as follows: *P < 0.05, **P < 0.01 and ***P < 0.001 (Kolmogorov–Smirnov
test). All behavioural paradigms were conducted on animals aged 8–10 weeks.
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showed a more diffuse distribution throughout the nucleoplasm
coupled with reduced heterochromatic localization. Diffuse
nuclear staining in comparison with WT-GFP and R306C-GFP
mutant proteins was more apparent at higher confocal laser in-
tensity, which showed background nuclear EGFP ﬂuorescence
in addition to heterochromatic localization (Supplementary Ma-
terial, Fig. S3D). This effect was more severe for T158M-GFP than
for R133C-GFP. An equivalent patternwas also seen in embryonic
stem cell-derived neurons in culture (Supplementary Material,
Fig. S3E). The results suggest compromised binding to mCG sites
by both these mutants, as explored below.
Compromised binding of MeCP2[R133C] and MeCP2
[T158M] to modiﬁed DNA in vivo and in vitro
Published evidence regarding the DNA binding afﬁnity of R133C
protein is inconsistent. South-western (10,22) and EMSA
(10,11,22,23) analyses revealed reduced binding of R133C to
Figure 4.R133C-GFPandT158M-GFPare less abundant thanWT-GFPandhave an abnormal pattern of sub-nuclear localization. (A) Graph showing level ofMecp2 transcript
normalized to Cyclophilin A in mutant male mouse brains relative to WT littermates (mean ± SD). WT-GFP, n = 9; R133C-GFP, n = 4; R306C-GFP, n = 3; T158M-GFP, n = 3. (B)
Quantiﬁcation of western blots showing levels of WT-GFP, R306C-GFP, R133C-GFP and T158M-GFP protein in male mouse brain, relative to WT (mean ± SEM). GT
served as an internal control; WT, n = 6; WT-GFP, n = 6; R133C-GFP, n = 3; R306C-GFP, n = 4; T158M-GFP, n = 6. (C) Representative images of the CA1 region of the
hippocampus in adult male mice from the allelic series. Slices were imaged using the same confocal settings. Immunoﬂuorescence was performed with DAPI (blue)
and anti-NeuN (red). MeCP2 was imaged by virtue of its EGFP tag. R133C-GFP and T158M-GFP show mixed punctate and diffuse sub-nuclear localization. Scale
bar = 20 μm. Statistical signiﬁcance is denoted as follows: *P < 0.05, **P < 0.01 and ***P < 0.001 (two-tailed unpaired t-test). All biochemical analyses were conducted using
tissues from adults aged 6–12 weeks.
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methylated DNA. Expression of R133C protein from an integrated
transgene in embryonic stem cells also revealed reduced speciﬁ-
city formethylatedDNA (24). On the other hand, surface plasmon
resonance indicated that the afﬁnity ofMeCP2 for CG-methylated
DNA is unaffected by the R133C mutation, whereas binding to
hydroxymethylated DNA is greatly reduced (15). In a transfection
assay, over-expressed R133C-GFP localized normally to hetero-
chromatin (12,24,25), although the mobility in a FRAP assay was
somewhat increased, compatible with a modest reduction in
afﬁnity for DNA (25,26). In view of the somewhat variable obser-
vations, we repeated EMSAs using either the methylated DNA
binding domain (MBD) alone (amino acids 77–167) or a larger
N-terminal fragment ofMeCP2 (amino acids 1–205). Interestingly,
these two polypeptides showed very different DNA binding afﬁn-
ities when carrying the R133C mutation. The 77–167 fragment of
R133C, which corresponds to the MBD alone, lost the ability to
form a stable complex with methylated DNA, whereas 1–205
[R133C] was essentially WT by an equivalent assay (Fig. 5A and
Figure 5. Defective binding of MeCP2[R133C] and T158M to modiﬁed DNA in vitro and in vivo. Representative gels and quantiﬁcation of EMSAs measuring MeCP2 peptide
binding tomCG probes using (A) aa77-167 or (B) aa1-205 fragments ofMeCP2with (green) or without (grey) the R133Cmutation. Mean percentage of probe shifted ± SEM is
plotted from three replicated experiments. Triangle represents decreasing peptide concentration; –, no peptide. Statistical signiﬁcance is denoted as: *P < 0.05,
**P < 0.01 and ***P < 0.001 (unpaired two-tailed t-test). (C) ChIP oligonucleotide duplex probes containing symmetrical mCG or hmCG, or asymmetrical mCA or hmCA
sites or both mCA and mCG sites together. Control DNA lacks all modiﬁcations. (D–G) Results of ﬁve independent transient transfection experiments followed by ChIP
of MeCP2-associated probe oligonucleotide fragments. Cells transiently expressed WT-GFP, R133C-GFP, T158M-GFP and R306C-GFP, respectively. Mean % input ± SD
plotted (n≥ 3).
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B). These opposing ﬁndings with a common probe and under the
same conditions recapitulate the spectrum of in vivo and in vitro
ﬁndings in the literature for this mutant, and they leave open
the question of whether this defect has any impact on chromatin
association in living cells.
To address this issue,weused acellularassay inwhich the vari-
ous forms of MeCP2 are over-expressed transiently at equivalent
levels in the presence of double-stranded oligonucleotides bearing
speciﬁc modiﬁcations of cytosine (S. Lagger et al., manuscript in
preparation). Themethodhas the advantage that it detects binding
of full-lengthprotein in living cellswhile allowing themodiﬁcation
status of the target DNA to be precisely deﬁned. In this way, we
could test binding not only to mCG, but also to methyl-CA (mCA)
and hydroxymethyl-CA (hmCA), which are all implicated as target
sequences for MeCP2 (27). Double-stranded oligonucleotides con-
taining either three symmetrically methylated mCGs, three
hmCGs or both mCA and mCGmodiﬁcations (Fig. 5C) were transi-
ently transfected intohumanembryonic kidney (HEK293) cells that
transiently expressedWTMeCP2-GFP (WT-GFP) ormutantMeCP2-
GFP from plasmid constructs. Unmodiﬁed oligonucleotides of the
same sequence served as controls. Recovery of the target DNA by
immunoprecipitation with anti-MeCP2 antibodies was monitored
by quantitative PCR (qPCR). The results showed preferential bind-
ing of WT-GFP protein to DNA containing mCA, mCG and, less ef-
ﬁciently, hmCA compared with non-methylated DNA, conﬁrming
the speciﬁcity of themethod (Fig. 5D). R306C-GFP, whosemissense
mutation is outside the DNA binding domain bound tomethylated
DNA indistinguishably from WT (Fig. 5G). Mutant R133C-GFP and
T158M-GFP proteins, in contrast, showed greatly impaired binding
toallmodiﬁedoligonucleotides (Fig. 5E and F). Importantly, protein
expression levels were closely similar between experiments (Sup-
plementary Material, Fig. S4), and therefore the effects of the
mutation on protein stability as seen in mouse brain do not affect
these results. Of particular note, the R133C mutation signiﬁcantly
compromises the interaction between MeCP2 and all modiﬁed oli-
gonucleotides in vivo, including mCG.
To examine the effects of mutations on MeCP2 binding in the
native genome in vivo, we quantitatively analysed R133C-GFP and
T158M-GFP binding in mouse brain by ChIP-qPCR using an anti-
EGFP antibody. For comparison, we also analysed WT-GFP and
R306C-GFP mutant proteins. The results showed that recovery
ofmouse satellite DNA, LINE1 elements, intracisternal A particles
and the gene for brain-derived neurotrophic factor (Bdnf ) from
cross-linked brain chromatin by R133C-GFP was reduced to
∼45–60% of the WT-GFP level, whereas T158M-GFP was 5–10%
ofWT-GFP (Fig. 6A). Binding of R306C-GFP proteinwas not signiﬁ-
cantly different from WT-GFP. We were concerned that reduced
binding of the two MBD mutants might reﬂect their low abun-
dance rather than an effect on binding afﬁnities per se. We there-
fore increased the stringency of cross-linking by reducing the
ﬁxation temperature on ice. Under these conditions, ChIP of the
R133C-GFP protein was reduced to ∼15% of the WT-GFP level,
which is signiﬁcantly greater than the reduction in protein abun-
dance of ∼50%. It was noticeable that under these stringent con-
ditions binding by R306C-GFPwas also compromised, as reported
by others (16), although this was not seen using our standard
cross-linking protocol (Fig. 6B). The ChIP results, together with
the in vitro data, transfection experiments and immunoﬂuores-
cence, suggest that both T158M-GFP and R133C-GFP mutant pro-
teins have a signiﬁcantly reduced afﬁnity for chromatin.
AsMeCP2 is proposed to bind to bothmCA- andhmC-contain-
ing DNA (16,27), we considered the possibility that the reduced
ChIP signal from R133C-GFP brain may be due to compromised
binding to these sequences rather than to mCG. To test this, we
Figure 6. Chromatin immunoprecipitation reveals abnormal binding of R133C-GFP to mCG-rich repetitive sequences and genes in mouse brain. (A) ChIP-qPCR of WT-
MeCP2 (lacking a GFP tag) and knocked-in WT-GFP, R133C-GFP, R306C-GFP and T158M-GFP in the adult male mouse brain. Primers amplify, respectively, major
satellite, LINE and IAP transposable elements and the Bdnf gene locus. The antibody was against GFP and therefore does not precipitate untagged WT MeCP2 (n≥ 3).
(B) Similar assay to (A) but with a lower and therefore more stringent cross-linking temperature (n = 4). (C) Column plot showing binding of R133C-GFP at the mCG-rich
cytochrome p450 locus by GFP ChIP (n = 3). (D) The same assay as (C) but using a more stringent cross-linking temperature. Plots are expressed as %WT-GFP value. Error
bars represent ± SEM, and statistical signiﬁcance is denoted as: *P < 0.05, **P < 0.01 and ***P < 0.001 (unpaired, two-tailed t-test). Each replicate experiment used tissue froma
separate animal. (E) Schematic of the Cyp3a57 locus depicting cytosinemethylation context. All biochemical analyseswere conducted using tissues from adults aged 6–12
weeks.
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probed immunoprecipitates for non-repetitive DNA sequences
that contain mCG, but very low levels of mCA and hmCG. The
∼900 kb cytochrome P450 gene locus, which is transcriptionally
silent in the brain, meets this requirement as whole-genome bi-
sulphite and TAB sequencing show a high level of CG methyla-
tion (28), while the other proposed MeCP2 binding sites, hmC
and mCH, are rare (Fig. 6E). Three of the genes from this locus,
Cyp3a25, Cyp3a57 and Cyp3a59 represented this pattern of
methylation and were selected for ChIP analysis. Again, recovery
of these sequences by ChIP was reduced in R133C-GFP brain ex-
tracts, reinforcing the conclusion that mCG binding by R133C-
GFP is signiﬁcantly compromised (Fig. 6C and D).
Modestly increased expression of long genes in the
cerebellum of R133C-GFP mice
Previous studies have detected subtle changes in gene expression
in the brains of mice that are Mecp2-null or carry RTT mutations
(29). We compared gene expression in cerebellums of R133C-GFP
and WT-GFP mice using expression microarrays, along with WT
and Mecp2-null mice for reference. The results initially showed
statistically signiﬁcant differences at six individual loci in
R133C-GFP cerebellum compared with WT-GFP, namely Abhd1,
Aplf, Dag1, Zfp428 (all down-regulated), Mybpc3 and Krt222
(up-regulated), but only two of these were reproduced by qPCR.
In one case, the effect was very small. In the other case (Abhd1),
the R133C-GFP expression was unchanged relative to WT or null
comparators. In fact, the variance in expression was attributable
to differences between WT-GFP cerebellum and the other tested
tissues (Supplementary Material, Fig. S5A). We explored the
data further by binning genes according to length to replicate re-
cent studies showing that long genes are disproportionately up-
regulated in Mecp2 mutant brains (27,30). The results showed a
small but sustained length-dependent increase in expression of
longer genes in R133C-GFP versus WT-GFP cerebellum (Supple-
mentary Material, Fig. S5B). In this study, the up-regulation of
long genes was modest in theMecp2-null versusWT cerebellum,
which was in agreement with previous similar analyses of this
brain region (27).
Discussion
MeCP2 is identical between human and mouse throughout the
greatmajority of its sequence, suggesting that almost all residues
of the protein are essential for full function. Despite long-range
conservation of the primary sequence across evolution, the dis-
tribution of missense mutations causing RTT is highly non-ran-
dom (13). Most missense mutations are concentrated in the MBD
and NID domains, disrupting the interaction with DNA and
NCoR/SMRT, respectively (7). All of the most common RTTmuta-
tions, including nonsense truncations, potentially involve C to T
transitions at CG sites and are therefore most likely caused by 5-
methylcytosine deamination coupled with failure of repair (31).
Their high frequency of occurrence therefore reﬂects elevated
mutability. The most common missense mutation is T158M,
which disrupts hydrogen-bonding integral to maintaining the
conﬁguration of an ASX turn (Asp156–Phe157–Thr158) and fol-
lowing STmotif (Thr158–Val159–Thr160–Gly161) in the C-termin-
al region of the MBD. This has been shown to destabilize MBD
structure and reduce afﬁnity for methylated DNA (20). Next
most frequent is R306C, which is located in the NID and prevents
the interaction of MeCP2 with the NCoR/SMRT co-repressor com-
plexes (13). Least severe on average of the common RTT muta-
tions is R133C, which mutates an arginine residue that in the
X-ray structure makes hydrogen bond contact with one of the
guanines in the symmetrical CG dyad (20). Individuals with this
mutation more frequently retain some speech and the ability to
walk (8,14). We found that phenotypic severity in mice matches
the respective clinical severity of these mutations in humans,
suggesting that the molecular basis of the resulting disorders is
the same in the two species.
The effects onDNAbinding ofMeCP2[T158M] toDNAare some-
what inconsistently reported in the literature. Previous in vitro stud-
ies of full-length T158M protein showed either mild (10) or severe
(22) impairment of mCG binding by South-western assay. EMSA
analysis, using the MBD fragment, also revealed ambiguous ﬁnd-
ings. Reduced binding to methylated DNA (10,20,23) was seen in
some instances but not others (11). Some of these discrepancies
may be attributed to the positions of N- and C-terminal afﬁnity
puriﬁcation tags (23). In vivo analysis ofmurine ﬁbroblasts over-ex-
pressing full-length MeCP2[T158M] indicated defective binding to
heterochromatic foci, and FRAP analysis showed greater mobility
of MeCP2[T158M] compared with WT protein, indicating a less
stable associationwith chromatin (25,26). Most published evidence
therefore supportstheview that theT158Mmutation compromises
binding betweenMeCP2 andmethylatedDNA.OurChIP data based
on transient transfection of cultured cells and brain conﬁrm this
defect in chromatin binding. These ﬁndings agreewith an analysis
of a different Mecp2 allelic variant involving the same amino acid,
T158A (6).
Molecular and cell biological assays allowed us to critically as-
sess a recent hypothetical explanation for the milder phenotype
in R133C-GFP mice. It was proposed that MeCP2[R133C] retains
WT levels of binding to mCG in vitro, but has speciﬁcally lost
the ability to interact with hydroxymethylated DNA (15). Our
ﬁndings place this hypothesis in doubt as several lines of evi-
dence show that mCG binding by MeCP2 is signiﬁcantly compro-
mised by this mutation: (i) immunoﬂuorescence analysis in
differentiated cultured neurons and in hippocampal sections
showed diffuse nuclear staining with reduced localization to
densely methylated heterochromatic foci; (ii) MBD DNA binding
in vitrowas defective by EMSA, in agreement with most previous
reports (though a longer fragment of MeCP2 displayed normal
binding); (iii) a cellular assay showed that full-length R133C-GFP
binding to mCG was greatly reduced; and (iv) ChIP analysis of
genomic regions where mCG was the only detectable modiﬁca-
tion showed greatly reduced binding by the mutant protein in
the brain. The brain ChIP data are particularly compelling, as
mouse satellite sequences and a gene cluster, both of which
lack hmC andmCH, showed impaired binding in vivo. In addition
to this loss of mCG binding, transfection experiments showed a
signiﬁcant reduction in MeCP2[R133C] binding to the alternative
canonical binding sites mCA and hmCA.
Despite occupying a key position in the MBD of MeCP2, the
R133C mutation results in a milder RTT phenotype and displays
residual mCG binding. These observations can be reconciled by
modelling the MeCP2–DNA interaction at a molecular level
(Fig. 7). The X-ray structure shows that two arginines, R133 and
R111, form equivalent hydrogen bonds with the two guanine
residues located on opposite strands at the self-complementary
dinucleotide sequence 5′CG (20) and also interact with 5-methyl-
cytosine (Fig. 7A). Replacement of R111 by glycine causes RTT, as
expected if DNA binding is severely disrupted. Substitution of
R133 by cysteine might be expected to have an equally severe ef-
fect, but in fact residual DNA binding persists. A notable differ-
ence between R111 and R133 is that the side chain of the
former adopts an all-trans extended conﬁguration and its side-
chain amino group is held in this position by aspartic acid 121
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via a hydrogen bond ‘clip’. Loss of this interaction probably has
structural consequences for the MBD as a whole. In contrast,
the R133 side chain is relatively untethered, forming a single
salt bridge with the carboxylate group of glutamate at position
137 (20). Replacement of R133 by the compact cysteine residue
is unlikely to impact the integrity of the MBD, but due to loss of
interactions with mC and G will reduce speciﬁcity. By placing a
hypothetical water molecule in the major groove, it is possible
to generate hydrogen bonding with G (Fig. 7B), which may ac-
count for the retention of weak DNA binding. We and others
have previously reported that WT MeCP2 fails to interact with
hmCG in vitro (27,32–34). As hmCG is by far the most abundant
setting for hmC in the brain (28), it is unclearwhichhmCmoieties
might be targeted in vivo. Further work may be needed to deﬁne
the full range of DNA binding speciﬁcities for both WT and mu-
tant forms of MeCP2.
The R306C mutation occurs outside the MBD of MeCP2 and
has no obvious effect on its stability, but may weakly affect chro-
matin binding (see also (16)). DNA binding impairment of this
protein domain has not been characterized biochemically and
was not detected in our cellular assay with full-length protein.
It is possible that it is indirect, due for example to differences in
extraction or altered association with partners. Further work is
needed to address this issue. The two MBD mutations T158M
and R133C, however, display both compromised stability and
weaker DNAbinding. Therefore, it is unlikely that a reduced afﬁn-
ity for chromatin alone underlies their clinical effects. In both
cases, MeCP2 abundance was found to be lower than WT-GFP
in knock-in mouse lines and when independent knock-in ESCs
were differentiated into neurons in culture. R133C-GFP exhibited
a less pronounced reduction in abundance (∼55%) in mice
comparedwith T158M-GFP (∼30%).We conclude that the reduced
abundance of T158M-GFP and R133C-GFP proteins is an intrinsic
property conferred on the protein by the respective mutations.
We speculate that the differing average severity associated with
these two mutations is primarily due to their contrasting abun-
dance. If both mutant proteins were present at the WT level,
through pharmacological stabilization or over-expression, we
speculate that they would exhibit similar pathologies at the
milder end of the RTT spectrum.
The introduction of speciﬁc RTT mutations into mice con-
ﬁrms the value of this model system in studying the molecular
basis of this condition. Generalizations are starting to emerge—
for example, three missense mutations (T158A, T158M and
R133C) have now been found to destabilize the protein and al-
most certainly make a signiﬁcant contribution to the phenotype
(this work and reference (6)). It is likely that the high abundance
ofMeCP2 in neurons is dependent to some extent on stability and
the highly conserved amino acid sequence may serve to insure
this. A measure of protein stability derived from gene ablation
studies in adult mice suggested that MeCP2 has a half-life of ∼2
weeks in the brain (19), which is longer than average. A second
generalization fromstudies ofmissensemutations is that disrup-
tion of the interactions between MeCP2 and DNA (R133C, T158M,
T158A) or between MeCP2 and NCoR (R306C) is associated with
RTT (13). It will be of interest to discover ifmodelling of additional
RTTmutations in mice adds to this list of molecular causes. This
information is likely to be essential in the search for rational
therapeutic approaches to mutation-speciﬁc aetiologies under-
lying this condition.
Materials and Methods
Knock-in of Mecp2 alleles
Targeting vectors to create EGFP-tagged alleles for WT Mecp2,
Mecp2R133C, Mecp2T158M and Mecp2R306C were constructed
using a 7.2-kb plasmid subclone of mouse 129/Ola genomic DNA
(3), including Mecp2 exons 3 and 4 (Supplementary Material,
Fig. S1). The coding sequence of EGFP was fused in-frame to the
end of the coding sequence of Mecp2 in exon 4 followed by a loxP-
ﬂanked NeoStop cassette as a selectable marker, retaining the
ﬁrst 1.8 kb of theMecp2 3′UTR as the 3′ homology arm. Pointmuta-
tions R133C, T158MandR306Cwere introduced into theWTMecp2-
EGFP targeting vector using the QuikChange II XL Site-Directed
Mutagenesis Kit (Agilent Technologies). Linearized constructs
were electroporated into 129/Ola E14 TG2amouse ES cells and cor-
rectly targeted clones identiﬁed by PCR screening and Southern
blotting (Supplementary Material, Fig. S1). Mice were generated
fromES cells by standard procedures (3). The loxP-ﬂanked selection
cassette was either removed in vitro for ES cell differentiation into
neurons by electroporation of targeted clones with pCAGGS-Cre
plasmid, or in vivo by test mating chimeras with the CMV-Cre del-
eter strain. Mice have been submitted to Jackson Laboratories
T158M-GFP: JAX Stock No. 26762 B6.Cg-Mecp2tm4.1Bird/J, R133C-GFP:
JAX Stock No. 26848 B6.Cg-Mecp2tm6.1Bird/J and R306C-GFP:JAX
Stock No. 26847 B6.Cg-Mecp2tm5.1Bird/J.
RNA extraction and qPCR
Frozenhalf brainswere homogenized in Tri Reagent (Sigma) using
the Ultra-Turrax T25. RNAwas extracted according to the manu-
facturer’s instructions. RNA was DNase I treated (DNA-free kit,
Ambion) and then reverse transcribed (iScript cDNA Synthesis
Kit, Bio-Rad) according to the manufacturer’s instructions. Fifty
Figure 7. Predictivemodelling ofMeCP2MBDbinding tomethylatedDNA reveals a
loss of speciﬁcity with the R133Cmutation. (A) Predictedmodel of MBD binding to
amethylated CpG pair. Arginine 111 and 133make contact with the guanines and
form hydrogen bonds with the methylcytosines of the CpG pair. Arginine 111
forms a hydrogen bond ‘clip’ with aspartic acid 121. (B) Predicted model of MBD
[R133C] binding to a methylated CpG pair. The cysteine 133 interaction with
guanine is now dependent on water molecules, and there is no signiﬁcant
interaction with the methylcytosine. (A and B) Hydrogen bonds are indicated by
dotted lines, methyl groups by green balls, and water molecules by grey and
orange balls.
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nanograms of cDNAwas ampliﬁed inqPCRusing SensiMix SYBR&
Fluorescein Master Mix (Bioline) with the following primers:
Me2Ex3/4 FWD ACCTTGCCTGAAGGTTGGAC, REV GCAATCAA
TTCTACTTTAGAGCGAAAA; CypA FWD TCGAGCTCTGAGCACTG
GAG and REV CATTATGGCGTGTAAAGTCACCA. Mecp2 mRNA
was normalized to Cyclophilin A housekeeping gene expression.
EGFP mutants were compared with WT littermates.
Protein extraction and western blot
One frozen half brain was homogenized in ice-cold NE1 buffer
[20 m Hepes pH 7.9, 10 m KCl, 1 mMgCl2, 0.1% Triton X-100,
20% glycerol, 0.5 mDTT, protease inhibitor (complete EDTA free
cocktail, Roche)] before adding 750 units of benzonase for 15 min
at room temperature then an equal volume of 2× SDS loading buf-
fer (0.125 M Tris pH 6.8, 20% glycerol, 4% SDS, 0.25% bromophenol
blue, 20 mDTT, 0.3 M β-mercaptoethanol). Sampleswere boiled
for 3 min before loading equal volumes on a 4–12% Run Blue
SDS precast gel (Expedeon). Gels were transferred to a 0.2-μm
nitrocellulose membrane (Bio-Rad) and then blocked for 1 h (5%
milk, 1× TBS, 0.1% Tween) before applying anti-Mecp2 1:1000
(Sigma M6818) or anti-γ-tubulin 1:3000 (Sigma T5326) overnight
at 4°C, followed by IRDye 800CW donkey anti-mouse IgG
1:10 000 (LiCor) for 2 h at RT after washing. Membranes were im-
aged using the Odyssey Infrared Imager (LiCor) and quantiﬁed
using Image Studio Lite Software (LiCor).
Phenotypic analysis
Mice tested were of fourth or ﬁfth generation back-crossed to
C57Bl/6J (N4 or N5). Scoring of symptoms and behavioural ana-
lyses were all performed blind to the genotype. Six parameters
were examined at the same time each week (activity, gait, hind-
limb clasping, tremor, breathing and general condition) and
given a score between 0 and 2, as previously described (19). Ani-
mals that scored 2 for tremor, breathing or general condition, or
which had lost 20% of their body weight had reached the severity
limit of the experiment according to the HomeOfﬁce License and
were humanely culled. Mice were also weighed weekly. Behav-
ioural analysis was done between 8 and 10 weeks in the order
(1) elevated plus maze, (2) hanging wire and then (3) accelerating
rotarod. For details of behavioural assays, see (19). In brief, for ele-
vated plusmaze,micewere placed in a cross-shapedmaze 65 cm
above the ﬂoorwith 2 open arms (20 × 8 cm), 2 closed arms (20 × 8
× 25 cm) and a central area (8 × 8 cm) in uniform dim lighting.
Time spent in open arms of the maze was visualized using
ANY-maze software (Stoelting). For the hanging wire, time
taken to bring one hind paw to a 1.5 mm diameter wire, 35 cm
above the bench, after mice were suspended by forepaws was re-
corded for up to 30 s over 3 trials, inter-trial interval 15 min. For
the accelerating rotarod, mice had one habituation training day
then time taken to fall from a 3 cm diameter rotating rod, accel-
erating between 4 and 40 RPM over 5 min was recorded. Mice had
4 trials per day (inter-trial interval 1 h) over 3 days.
Immunoﬂuorescence
Mice were perfused with 3.7% paraformaldehyde in PBS, pH 7.4,
then immersion ﬁxed overnight. The brains were then dehy-
drated in 30% sucrose for 24 h, washed brieﬂy in PBS, blotted
dry, halved and snap frozen in isopentane cooled on dry ice.
The brains were sectioned at 10 μm (Leica CM 1900 Cryostat)
and mounted. Slides were washed in PBS, permeabilized in
0.1% Triton X-100 for 15 min, washed, blocked for 1 h at RT in
1.5% normal goat serum, stained with anti-NeuN-Cy3 1:100
(MAB377C3 Millipore) overnight at 4°C then ﬁnally, washed,
stained with 1 μg/ml DAPI and washed again. Slides were
mounted in Prolong Gold Antifade Reagent (Molecular Probes).
The brains were visualized on a LeicaSP5 Confocal Laser Scan-
ning Microscope. For clarity, a set of images were taken where
the EGFP signal was optimized for each genotype individually.
A look-up table (LUT) was applied to hippocampal CA1 images,
where blue pixels denoted over-saturation and green pixels de-
noted zero. Photonmultiplier tube (PMT) gain was kept constant,
and laser power was adjusted until one or two pixels were blue
and as few pixels as possible were green. These settings were
saved and used for all subsequent images for that genotype.
Electrophoretic mobility shift assays
Recombinant MeCP2 protein expression vectors were constructed
with a C-terminal histidine tag in the bacterial expression plasmid
pET30b (Novagen). The R133C pointmutationwas introduced into
the WT plasmid using QuikChange II XL Site-Directed Mutagen-
esis Kit (Agilent Technologies) as per the manufacturer’s instruc-
tions. BL21(DE3)pLysS competent cells were transformed, and a
scrape of colonies was inoculated in a starter culture overnight,
then into 500 mlwarmLB (50 μg/ml kanamycin; 17 μg/ml chloram-
phenicol) and shaken at 37°C. Cultures were induced with 1 m
IPTG when the OD was 0.6–0.8 at 600 nm and then grown at 30°C
for 3 h. Pellets were mashed in ice-cold lysis buffer [50 m
NaH2PO4, 100 m NaCl, 10% glycerol, 30 m imidazole, 0.1%
NP40, protease inhibitor (complete EDTA free cocktail, Roche),
pH 7.5] and passed through a 21G needle prior to adding 750
units of benzonase then being sonicated 30 s on/off for 10 cycles
(Branson Digital Soniﬁer). Samples were adjusted to 0.3 M NaCl,
and then after centrifugation, 0.5 ml bead volume NiSO4-coated
ChelatingSepharose Fast Flowbeads (GEHealthcare) in lysis buffer
was added to lysates for 1 h at 4°C. Beads were washed 3 times in
lysis buffer before MeCP2 polypeptides were eluted with 250 m
imidazole lysis buffer in 5 fractions. Eluted fractions were pooled,
adjusted to 1 m EDTA and then dialysed [Slide-A-Lyzer Dialysis
Cassette 7 K MWCO (Thermo Scientiﬁc)] overnight at 4°C in 0.1 M
HEPES buffer (20 m HEPES pH7; 100 m NaCl; 1 m EDTA;
5 m β-mercaptoethanol). The polypeptides underwent a second
puriﬁcation stepandwere eluted fromaHiTrapSPHP1 mlColumn
(GE Healthcare) using a 0.7 M NaCl HEPES buffer. An oligonucleo-
tide probe from the mouse Bdnf promoter region 5′ AAGCATG
CAATGCCCTGGAACGGAATTCTTCTAATAAAAGATGTATCATTTTA
AATGC 3′ (Biocore), plus complementary reverse strand, was
methylated or unmethylated at the central CG indicated in bold
italics. Five hundred nanograms of probe was radio-labelled
using T4 polynucleotide kinase (NEB) and puriﬁed (MinElute PCR
Puriﬁcation Kit, Qiagen) according to the manufacturer’s instruc-
tions. One nanogram probe and 1 μg poly deoxyadenylic-thy-
midylic acid competitor DNA (Sigma-Aldrich) were added to
polypeptide in reaction buffer (5% glycerol, 0.1 m EDTA, 10 m
TrisHClpH7.5, 150 mKCl, 0.1 mg/mlBSA) on ice for 20 min. Sam-
ples were run at 120 V for 70min on a 10% acrylamide tris borate
EDTA gel (0.075% APS, 0.00125% TEMED) in chilled TBE. The gels
were exposed overnight and imaged using the Typhoon FLA
9500 scanner (GE Healthcare). Percentage shift was calculated
using Image J software.
Cellular immunoprecipitation
Using Lipofectamine 2000 (Life technologies), 1.5 × 106HEK 293 FT
cells were transfected over night with 0.5 μg of MeCP2 WT or
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R133C, T158M and R306C mutants tagged with EGFP, according to
the manufacturer’s instructions. After assessment of transfection
efﬁciency, the medium was changed and cells were transfected
withannealedunmodiﬁedormethylatedoligonucleotides (100 nM)
ﬁnal concentration using TransIT Oligofect reagent (Mirus) for 4 h.
Cells werewashedwith PBS and harvested by trypsinisation. In the
next step, cells were cross-linked with 1% formaldehyde for 5 min
at room temperature and quenched by the addition of glycine to a
ﬁnal concentration of 0.125 M for 5 min. At this stage, cell pellets
could be ﬂash frozen in liquid nitrogen and stored at −80°C or
directly used for DNA–protein complex isolation and consecutive
IP. Oligonucleotide sequence: 5′ ATGCTAATTAACCCTCACTAAA
GGGAACTCGAGACATCGGAGAATTCACATCACCGGTGAATCAGTGC
TACCCGCAAGTGCACTGGATCCACTGGCCGTCGTTTTACAA 3′. The
transfected fragment consisted of an artiﬁcial sequence (49% GC
content) ﬂanked by T3 andM13-20 primer binding sites for unique
ampliﬁcation. Primer sequences are underlined. Differentially
methylated CGs are highlighted in bold. Soluble chromatin prepar-
ation and chromatin immunoprecipitation assays were carried out
as described previously with modiﬁcations. In short, chromatin
was sonicated using a Twin Bioruptor (Diagenode) 30 s on/off for
15 cycles. Equal amounts of chromatin were used for IP with 5 μg
MeCP2 M6818 antibody (Sigma) and incubated overnight. Protein–
antibody complexes were bound to magnetic protein G beads
(Life technologies) for 4–5 handwashedwithstandard IPwashbuf-
fers for 10 min at 4°C. The cross-link was reversed by addition of
0.05 volume of 4 M NaCl over night at 65°C. After proteinase K di-
gestion, DNAwas recovered byphenol–chloroform–isoamylalcohol
extraction and dissolved in 200 μl H2O. Real-time PCR of ChIP DNA
and corresponding input DNAwas performedusing T3 andM13-20
primers.
Brain chromatin immunoprecipitation
Frozen half brains were Dounce homogenized in 1 ml PBS and
then ﬁxed in 1% formaldehyde for 1 min at room temperature
or 60 s after being on ice (stringent ChIP) before quenching with
250 m glycine. Chromatin immunoprecipitation assays were
carried out as described previously with modiﬁcations. In short,
chromatinwas sonicated using aTwin Bioruptor (Diagenode) 30 s
on/off for 15 cycles. Equal amounts of chromatin were used for IP
with 40 μl GFP-Trap_A beads (Chromotek) and rotated for 1.5 h at
4°C. Protein–antibody complexes were washed with standard IP
wash buffers for 4 min at 4°C. The cross-link was reversed by
addition of 0.05 volume of 4 M NaCl overnight at 65°C. After
proteinase K digestion, DNA was recovered by phenol–chloro-
form–isoamylalcohol extraction and dissolved in 200 μl H2O.
Real-time PCR of ChIP DNA and corresponding input DNA was
performed using speciﬁc primers. Major Satellite FWD GGC
GAGAAAACTGAAAATCACG, REVAGGTCCTTCAGTGTGCATTTC;
LINE1 Elements FWD TTTGGGACACAATGAAAGCA, REV CTGCC
GTCTACTCCTCTTGG; IAP FWD GAGATTGGACTTTTGACTTGT,
REV TGTGGCTTGCTCATAGATTAG; Bdnf FWD TTCGATTCACG
CAGTTGTTC, REV CTGAGCCAGTTACGTGACCA; Cyp3a25 FWD
CAGGTTTGGGGTGTTGTGAA, REV CTGCAGCTGTTGTGGGAG;
Cyp3a57 FWD GTGCTGCTCTTACATGGCTG, REV GTGGGGCTA
CAGTCTATGCT; Cyp3a59 FWD CCTGACTGGCTGCTCACTAT, REV
AGGCTGTGAACTATAGGAGCC.
Statistics
Behavioural data were analysed using the Kolmogorov–Smirnov
test with the Benjamini and Hochberg method of correction for
false discoverywithmultiple testing. Survival datawere analysed
using theMantel-Cox test. Biochemical datawere analysed using
two-tailed, unpaired t-tests.
Study approval
Mice were maintained under standard conditions and in accord-
ance with UK Home Ofﬁce regulations and licenses.
Supplementary Material
Supplementary Material is available at HMG online.
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